Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Kerry L. Thomas
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, Kerry Thomas wrote the following 2 articles about Melanoma.
+ Citations + Abstracts
1 Article Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. 2018

Karydis, Ioannis / Gangi, Alexandra / Wheater, Matthew J / Choi, Junsung / Wilson, Iain / Thomas, Kerry / Pearce, Neil / Takhar, Arjun / Gupta, Sanjay / Hardman, Danielle / Sileno, Sean / Stedman, Brian / Zager, Jonathan S / Ottensmeier, Christian. ·Cancer Sciences Academic Unit, University of Southampton, Southampton, United Kingdom. · University Hospital Southampton, Southampton, United Kingdom. · Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. · Department of Radiology, Moffitt Cancer Center, Tampa, Florida. · Morsani School of Medicine, University of South Florida, Tampa, Florida. ·J Surg Oncol · Pubmed #29284076.

ABSTRACT: BACKGROUND: Metastatic uveal melanoma (UM) carries a poor prognosis; liver is the most frequent and often solitary site of recurrence. Available systemic treatments have not improved outcomes. Melphalan percutaneous hepatic perfusion (M-PHP) allows selective intrahepatic delivery of high dose cytotoxic chemotherapy. METHODS: Retrospective analysis of outcomes data of UM patients receiving M-PHP at two institutions was performed. Tumor response and toxicity were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events (CTCAE) v4.03, respectively. RESULTS: A total of 51 patients received 134 M-PHP procedures (median of 2 M-PHPs). 25 (49%) achieved a partial (N = 22, 43.1%) or complete hepatic response (N = 3, 5.9%). In 17 (33.3%) additional patients, the disease stabilized for at least 3 months, for a hepatic disease control rate of 82.4%. After median follow-up of 367 days, median overall progression free (PFS) and hepatic progression free survival (hPFS) was 8.1 and 9.1 months, respectively and median overall survival was 15.3 months. There were no treatment related fatalities. Non-hematologic grade 3-4 events were seen in 19 (37.5%) patients and were mainly coagulopathic (N = 8) and cardiovascular (N = 9). CONCLUSIONS: M-PHP results in durable intrahepatic disease control and can form the basis for an integrated multimodality treatment approach in appropriately selected UM patients.

2 Article Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma. 2018

Abbott, Andrea M / Doepker, Matthew P / Kim, Youngchul / Perez, Matthew C / Gandle, Cassandra / Thomas, Kerry L / Choi, Junsung / Shridhar, Ravi / Zager, Jonathan S. ·Departments of Cutaneous Oncology. · Biostatistics and Bioinformatics. · Radiology. · Interventional Radiology. · Radiation Oncology, Moffitt Cancer Center, Tampa, FL. ·Am J Clin Oncol · Pubmed #28059929.

ABSTRACT: OBJECTIVES: Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) were evaluated. MATERIALS AND METHODS: A retrospective review of patients with liver metastases from cutaneous or uveal melanoma treated with yttrium-90 (Y90), chemoembolization (CE), or percutaneous hepatic perfusion (PHP) was conducted. RESULTS: Thirty patients (6 Y90, 10 PHP, 12 CE, 1 PHP then Y90, 1 CE then PHP) were included. Multivariate analysis showed improved HPFS for PHP versus Y90 (P=0.004), PHP versus CE (P=0.02) but not for CE versus Y90. PFS was also significantly different: Y90 (54 d), CE (52 d), PHP (245 d), P=0.03. PHP treatment and lower tumor burden were significant predictors of prolonged PFS on multivariate analysis. Median OS from time of treatment was longest, but not significant, for PHP at 608 days versus Y90 (295 d) and CE (265 d), P=0.24. Only PHP treatment versus Y90 and lower tumor burden had improved OS on multivariate analysis (P=0.03, 0.03, respectively). CONCLUSIONS: HPFS and PFS were significantly prolonged in patients treated with PHP versus CE or Y90. Median OS in PHP patients was over double that seen in Y90 or CE patients but was significant only between PHP and Y90.